Sutro Biopharma, Inc. (STRO) Earnings History
Annual and quarterly earnings data from 2016 to 2024
Loading earnings history...
STRO EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
STRO Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 88.4% | -384.3% | -366.6% |
| 2023 | 95.6% | -58.1% | -69.5% |
| 2022 | 87.8% | -190.3% | -175.9% |
| 2021 | 84.2% | -159.2% | -170.6% |
| 2020 | -80.1% | -166.3% | -75.2% |
Download Data
Export STRO earnings history in CSV or JSON format
Free sign-in required to download data
Sutro Biopharma, Inc. (STRO) Earnings Overview
As of May 8, 2026, Sutro Biopharma, Inc. (STRO) reported trailing twelve-month net income of -$217M, reflecting -66.3% year-over-year growth. The company earned $-25.54 per diluted share over the past four quarters, with a net profit margin of -366.6%.
Looking at the long-term picture, STRO's historical earnings data spans multiple years. The company achieved its highest annual net income of $2M in fiscal 2016.
Sutro Biopharma, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RCUS (-$369M net income, -142.9% margin), BOLT (-$33M net income, -433.7% margin), NKTR (-$164M net income, -297.1% margin), STRO has room to improve margins relative to the peer group. Compare STRO vs RCUS →
STRO Earnings vs Peers
Earnings metrics vs comparable public companies
STRO Historical Earnings Data (2016–2024)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$227M | -113.0% | -$238M | $-29.60 | -366.6% | -384.3% |
| 2023 | -$107M | +10.4% | -$89M | $-17.80 | -69.5% | -58.1% |
| 2022 | -$119M | -12.9% | -$129M | $-23.50 | -175.9% | -190.3% |
| 2021 | -$106M | -228.5% | -$99M | $-22.90 | -170.6% | -159.2% |
| 2020 | -$32M | +42.4% | -$71M | $-9.90 | -75.2% | -166.3% |
| 2019 | -$56M | -57.8% | -$55M | $-24.30 | -130.4% | -129.8% |
| 2018 | -$35M | -79.4% | -$37M | $-15.40 | -91.9% | -96.9% |
| 2017 | -$20M | -1256.8% | -$19M | $-28.10 | -38.1% | -37.2% |
| 2016 | $2M | - | $1M | $38.60 | 2.8% | 2.3% |
See STRO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs STRO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare STRO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSTRO — Frequently Asked Questions
Quick answers to the most common questions about buying STRO stock.
Is STRO growing earnings?
STRO EPS fell to $-25.54, with earnings declining -66.3%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-217M.
What are STRO's profit margins?
Sutro Biopharma, Inc. net margin is -366.6%, with operating margin at -384.3%. Below-average margins reflect competitive or cost pressures.
How consistent are STRO's earnings?
STRO earnings data spans 2016-2024. The declining earnings trend is -66.3% YoY. Historical data enables comparison across business cycles.